Description
Lenalidomide displays anti-inflammatory, anti-angiogenic, immunosuppressive, and anticancer chemotherapeutic benefits in the treatment of multiple myeloma and myelodysplastic syndromes associated with chromosome 5q deletions. Lenalidomide is a derivative of thalidomide and is also currently in clinical trials as a potential treatment for several lymphomas and leukemias; like thalidomide, it may inhibit TNF-α and cereblon. In vitro, lenalidomide upregulates both BH3-interacting domain death agonist (BID) and FOS and downregulated NKX2-1, increasing apoptosis and inhibiting cell proliferation. Additionally, this compound inhibits VEGF-induced PI3K-Akt signaling as well as expression of HIF-1α.
References
Kim K, An S, Cha HJ, et al. Lenalidomide induces apoptosis and alters gene expression in non-small cell lung cancer cells. Oncol Lett. 2013 Feb;5(2):588-592. PMID: 23420263.
Chen Y, Borthakur G. Lenalidomide as a novel treatment of acute myeloid leukemia. Expert Opin Investig Drugs. 2013 Mar;22(3):389-97. PMID: 23316859.
Lu L, Payvandi F, Wu L, et al. The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res. 2009 Mar;77(2):78-86. PMID: 18805433.
Vallet S, Palumbo A, Raje N, et al. Thalidomide and lenalidomide: Mechanism-based potential drug combinations. Leuk Lymphoma. 2008 Jul;49(7):1238-45. PMID: 18452080.
